scholarly journals Aortic valve bypass for high‐risk patients with symptomatic aortic stenosis: A case report

2021 ◽  
Author(s):  
Yanqiong Ye ◽  
Changjiang Yu ◽  
Ximing Qian
Keyword(s):  
Case Report ◽  
High Risk ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
High Risk Patients ◽  
Risk Patients ◽  
Aortic Valve Bypass

P914Balloon aortic valve valvuloplasty as palliative therapy in severe aortic valve stenosis: 10 years experience in a single centre

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
F Mantovani ◽  
M A Clavel ◽  
F Jayme ◽  
L Valli ◽  
R M De Mola ◽  
...  
Keyword(s):  
Heart Failure ◽  
High Risk ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
Palliative Therapy ◽  
Medical Attention ◽  
High Risk Population ◽  
High Risk Patients ◽  
Risk Patients

Abstract Background Improved technology together with greater operator experience has led to refinement of balloon aortic valve valvuloplasty (BAV) in recent years. It may provide a palliative treatment option in high-risk patients, highly symptomatic, for whom no other invasive therapy is available. However, there has not been universal adoption of BAV as a standalone therapy. Methods A retrospective analysis of ten years of practice of BAV as palliative strategy in patient with symptomatic aortic stenosis between March 2008 and June 2018 was performed. Demographic, clinical, procedural, and follow-up data on all patients were collected. Results A total of 152 patients (95 women, 63%) with a mean age of 85±6 years underwent BAV. All patients had severe aortic stenosis, were considered not suitable to aortic valve replacement nor Trans-catheter aortic valve implantation (TAVI) for appreciable comorbidity (STS score 9±5) and had severe symptoms mainly of heart failure which required medical attention. A statistically significant decrease in trans-valvular gradient was observed (peak to peak gradient before BAV 52±22 mmHg, after BAV 29±16 mmHg, delta gradient 24±14 mmHg; p<0.0001). Only one patient, who undergone BAV because of cardiogenic shock, died during the procedure. Considering the high-risk population, intra-hospital mortality was low (7 patients died, 4%). Mortality at 1-year follow-up was 43% and survival free from new hospitalization for heart failure was 63% at 1-year follow-up and 53% at 2 years follow-up. 19 patients (13%) required repeated BAV during follow-up. Conclusion BAV as a palliative procedure in high-risk patients who are highly symptomatic, has a low operative mortality in our experience. BAV is associated with a significant reduction in aortic valve gradient and is valuable since half of the patients were alive without re-hospitalizations for heart failure at 2 years follow-up. Acknowledgement/Funding None

Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis – Overcoming the Challenges

2011 ◽  
Vol 6 (2) ◽  
pp. 165 ◽  
Author(s):  
Thomas Walther ◽  
Helge Möllmann ◽  
Johannes Blumenstein ◽  
Jörg Kempfert ◽  
◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
Transcatheter Aortic Valve Implantation ◽  
Heart Team ◽  
High Risk Patients ◽  
Transcatheter Aortic Valve ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Transcatheter aortic valve implantation (TAVI) has evolved as one of the most important innovations in cardiovascular medicine during the past five years. By means of transfemoral (TF) and transapical (TA) AVI elderly and high-risk patients with symptomatic aortic stenosis (AS) are being routinely treated using a minimally invasive approach. Some challenges have to be overcome to obtain perfect results: patient screening and eventual selection is important, conduct of the procedures by an experienced and interdisciplinary heart team is ideal and intense post-operative therapy is required for the patients. Currently available devices, the Corevalve™ (CV, Medtronic Inc.) and SAPIEN™ (ES, Edwards Inc.) prostheses, which are Conformité Européenne (CE) Mark approved for TF (CV and ES) and TA (ES) implantations, are first-generation prostheses. Future developments will focus on reduction of potential paravalvular leakage as well as improved features during valve implantation, most importantly repositioning and retrievability. TAVI has already gained an important position for the treatment of elderly high-risk patients with AS.

scholarly journals Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis

2017 ◽  
Vol 70 (25) ◽  
pp. 3127-3136 ◽  
Author(s):  
Hermann Reichenspurner ◽  
Andreas Schaefer ◽  
Ulrich Schäfer ◽  
Didier Tchétché ◽  
Axel Linke ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
Severe Aortic Stenosis ◽  
Valve System ◽  
High Risk Patients ◽  
Transcatheter Aortic Valve ◽  
Risk Patients
Sign in / Sign up

Export Citation Format

Share Document